Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del (5q) karyotypes

British Journal of Haematology

Volumn 123, Issue 5, 2003, Pages 879-885

  Stewart, B ^a   Verdugo, M ^a   Guthrie, K A ^a   Appelbaum, F ^a   Deeg, H J ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

5q ; Haematopoietic cell transplantation; MDS

Indexed keywords

5Q- SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; BLAST TRANSFORMATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CELL COUNT; CHILD; CHROMOSOME 5Q; CHROMOSOME DELETION 5; CONTROLLED STUDY; CYTOPENIA; DISEASE COURSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REFRACTORY ANEMIA; RISK FACTOR; TREATMENT INDICATION; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANEMIA, REFRACTORY; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; CAUSE OF DEATH; CHILD; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECURRENCE; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 0347480379     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04713.x     Document Type: Article

References (20)

1. Anderson, J.E., Appelbaum, F.R., Schoch, G., Gooley, T., Anasetti, C., Bensinger, W.I., Bryant, E., Buckner, C.D., Chauncey, T., Clift, R.A., Deeg, H.J., Doney, K., Flowers, M., Hansen, J.A., Martin, P.J., Matthews, D.C., Nash, R.A., Sanders, J.E., Shulman, H., Sullivan, K.M., Witherspoon, R.P. & Storb, R. (1996) Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. Journal of Clinical Oncology, 14, 220-226.
2. Anderson, J.E., Appelbaum, F.R., Schoch, G., Barnett, T., Chauncey, T.R., Flowers, M.E.D. & Storb, R. (2001) Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation. Biology of Blood & Marrow Transplantation, 7, 163-170.
3. Bornhauser, M., Storer, B., Slattery, J.T., Appelbaum, F.R., Deeg, H.J., Hansen, J., Martin, P.J., McDonald, G.B., Nichols, G., Radich, J., Woolfrey, A., Jenke, A., Schleyer, E., Thiede, C., Ehninger, G. & Anasetti, C. (2003) Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood, 102, 820-826.
4. Cermak, J., Michalova, K., Brezinova, J. & Zemanova, Z. (2003) A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q-syndrome from refractory anemia In primary myelodysplastic syndrome. Leukemia Research, 27, 221-229.
5. Christiansen, D.H., Andersen, M.K. & Pedersen-Bjergaard, J. (2001) Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. Journal of Clinical Oncology, 19, 1405-1413.
6. Cutler, C., Lee, S., Greenberg, P., Deeg, J., Antin, J., Perez, W. & Horowitz, M. (2002) A decision analysis of allogeneic stem cell transplantation for MDS: delayed transplantation for low risk MDS is associated with improved outcome. Blood, 100(part 1), 74 (abstract no. 270).
7. Deeg, H.J., Storer, B., Slattery, J.T., Anasetti, C., Doney, K.C., Hansen, J.A., Kiem, H.-P., Martin, P.J., Petersdorf, E., Radich, J.P., Sanders, J.E., Shulman, H.M., Warren, E.H., Witherspoon, R.P., Bryant, E.M., Chauncey, T.R., Getzendaner, L., Storb, R. & Appelbaum, F.R. (2002) Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood, 100, 1201-1207.
8. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes (published erratum appears in Blood 1998; 91: 1100). Blood, 89, 2079-2088.
9. Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. & Bloomfield, C.D. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting - Airlie House, Virginia, November 1997. Journal of Clinical Oncology, 17, 3835-3849.
10. Jurado, M., Deeg, H.J., Storer, B., Anasetti, C., Anderson, J.E., Bryant, E., Chauncey, T., Doney, K., Flowers, M.E.D., Hansen, J., Martin, P.J., Nash, R.A., Petersdorf, E., Radich, J., Sale, G., Sandmaier, B.M., Storb, R., Wade, J., Witherspoon, R. & Appelbaum, F.R. (2002) Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biology of Blood and Marrow Transplantation, 8, 161-169.
11. LeBeau, M.M. & Larson, R.A. (2000) Cytogenetics and neoplasia. In: Hematology: Basic Principles and Practice (ed. by R. Homan, E.J. Benz, S.J. Shattil, B. Furie, H.J. Cohen, L.E. Silberstein & P. McGlave), p. 848-870. Churchill Livingstone, New York.
12. Maris, M., Niederwieser, D., Sandmaier, B., Maloney, D., Shizuru, J., Petersdorf, E., Blume, K., Chauncey, T., Pulsipher, M., McSweeney, P., Storer, B., Anasetti, C., Woolfrey, A., Slattery, J., Agura, E., Little, M.-T., Hegenbarth, U. & Storb, R. (2001) Non-myeloablative hematopoietic stem cell transplants (HSCT) using 10/10 HLA antigen matched unrelated donors (URDs) for patients with advanced hematologic malignancies ineligible for conventional HSCT. Blood, 98(part 1), 858 (abstract no. 3563).
13. Martin, P., Nash, R., Sanders, J., Leisenring, W., Anasetti, C., Deeg, H.J., Storb, R. & Appelbaum, F. (1998) Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation. Bone Marrow Transplantation, 21, 273-279.
14. Morel, P., Hebbar, M., Lai, J.-L., Duhamel, A., Preudhomme, C., Wattel, E., Bauters, F. & Fenaux, P. (1993) Cytogenetic analysis has strong Independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia, 7, 1315-1323.
15. Nevill, T.J., Fung, H.C., Shepherd, J.D., Horsman, D.E., Nantel, S.H., Klingemann, H.G., Forrest, D.L., Toze, C.L., Sutherland, H.J., Hogge, D.E., Naiman, S.C., Le, A., Brockington, D.A. & Barnett, M.J. (1998) Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood, 92, 1910-1917.
16. Petersdorf, E.W., Hansen, J.A., Martin, P.J., Woolfrey, A., Malkki, M., Gooley, T., Storer, B., Mickelson, E., Smith, A. & Anasetti, C. (2001) Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. New England Journal of Medicine, 345, 1794-1800.
17. Sanz, G.F. & Sanz, M.A. (1992) Prognostic factors in myelodysplastic syndromes (review). Leukemia Research, 16, 77-86.
18. Sullivan, K.M. (1999) Graft-versus-host-disease. In: Hematopoietic Cell Transplantation, 2nd edn (ed. by E.D. Thomas, K.G. Blume & S.J. Forman), p. 515-536. Blackwell Science, Boston.
19. Washington, L.T., Doherty, D., Glassman, A., Martins, J., Ibrahim, S. & Lai, R. (2002) Myeloid disorders with deletion of 5q as the sole karyotypic abnormality: the clinical and pathologic spectrum. Leukemia & Lymphoma, 43, 761-765.
20. Wells, D.A., Benesch, M., Loken, M.R., Vallejo, C., Myerson, D., Leisenring, W.M. & Deeg, H.J. (2003) Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastlc syndrome correlates with the IPSS and with outcome after hemopoietic stem cell transplantation. Blood, 102, 394-403.